HOOKIPA PHARMA INC. DelveInsight's, "Squamous Cell Carcinoma Pipeline Insight, 2024" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Squamous Cell Carcinoma pipeline landscape. It covers the Squamous Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Squamous Cell Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in
Key Takeaways from the Squamous Cell Carcinoma Pipeline Report*
Stay informed about the cutting-edge advancements in Squamous Cell Carcinoma Treatments. Download for updates and be a part of the revolution in cancer care @ Squamous Cell Carcinoma Clinical Trials Assessment
Squamous Cell Carcinoma Emerging Drugs Profile*NBTXR-3:
NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with squamous cell carcinoma.*mRNA-4157:
mRNA-4157 is an investigational personalized mRNA cancer vaccine, Merck's anti-PD-1 therapy, for the adjuvant treatment of patients with squamous cell carcinoma. The drug is currently being evaluated under Phase II/III clinical trial for the treatment of patients with squamous cell carcinoma.*HB-200:
HB-200 is HOOKIPA's lead oncology candidate engineered with the company's proprietary replicating arenaviral vector platform. HB-200 is an alternating 2-vector immunotherapy designed to focus the immune response against the encoded antigen. It comprises two single-vector compounds with arenaviral backbones based on LCMV and PICV. Both encode and express an identical E7E6 fusion protein, comprising well characterized tumor-specific antigens for HPV16+ cancers. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with squamous cell carcinoma.*MCLA-158: Merus
MCLA-158 (also known as Petosemtamab) is a Biclonics low-fucose human full-length IgG1 antibody targeting the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5). The drug is designed to exhibit three independent mechanisms of action including inhibition of EGFR-dependent signaling, LGR5 binding leading to EGFR internalization and degradation in cancer cells, and enhanced antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis activity. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with squamous cell carcinoma.*HFB-301001: HiFiBiO
HFB301001 is a novel fully human IgG1 class OX-40 agonistic antibody with an optimized pharmacological profile. In contrast to other anti-OX-40 antibodies, the agonistic activity of HFB301001 is further enhanced in the presence of the endogenous ligand OX-40L and does not result in reduced expression of OX-40 on T cells. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with squamous cell carcinoma.
Learn more about Squamous Cell Carcinoma Drugs opportunities in our groundbreaking
Squamous Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.*Intravenous *Subcutaneous *Oral *Intramuscular
Squamous Cell Carcinoma Products have been categorized under various Molecule types such as*Monoclonal antibody *Small molecule *Peptide
Discover the latest advancements in Squamous Cell Carcinoma Treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Squamous Cell Carcinoma Market Drivers and Barriers, and Future Perspectives
Squamous Cell Carcinoma Companies and Therapies*
Scope of the Squamous Cell Carcinoma Pipeline Report*Coverage- Global *Squamous Cell Carcinoma Companies-
For a detailed overview of our latest research findings and future plans, read the full details of Squamous Cell Carcinoma Pipeline on our website @ Squamous Cell Carcinoma Drugs and Companies
Table of Content*Introduction *Executive Summary *Squamous Cell Carcinoma: Overview *Pipeline Therapeutics *Therapeutic Assessment *Squamous Cell Carcinoma- DelveInsight's Analytical Perspective *Late Stage Products (Phase III) *NBTXR-3:
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company
Contact Person:
Email: ybhardwaj@delveinsight.com
Phone: +14699457679
Address:
City:
State: NV
Country:
Website: https://www.delveinsight.com/
Source: www.abnewswire.com
.
(C) 2024 M2 COMMUNICATIONS, source
